Analgesics

Analgesics had been in decline prior to the onset of COVID-19 in Switzerland. Consumers have become cautious about the potential adverse side effects of analgesics if used regularly over a long period of time, as warned by the medical establishment ...

Analgesics has seen similar growth in 2020 to that seen in 2019 in current value terms, although COVID-19 has nonetheless had an impact on the sale, supply, and distribution of these products in Austria. As concerns started to rise around the threat ...

After double-digit growth in sales in March 2020, sale of analgesics in Germany suffered a severe contraction in April as the ‘’boom’’ effect of stockpiling products wore off. In the initial stages of the pandemic, local consumers stocked up on ...

Acetaminophen, particularly paediatric acetaminophen, will see strong current retail value growth in 2020, driven by Genomma Laboratories’ strong investment. The impact of COVID-19, along with the Dengue outbreak which, until May 2020, had a higher ...

As seen throughout the review period, analgesics is expected to maintain double-digit current value growth in 2020, with a slightly higher growth rate than seen in the previous few years. The demand for analgesics increased significantly in the first...

COVID-19 caused a spike in demand for analgesics, meaning analgesics is expected to see an even stronger increase in retail current value growth in 2020 when compared to 2019. This is due to the fact that the government in Uruguay initially ...

The COVID-19 outbreak led to stockpiling among consumers. They generally purchased adult acetaminophen, and paediatrician acetaminophen, which are considered safe and effective in offering relief from a variety of symptoms, particularly fever and ...

After seeing moderate retail current value growth in 2019, analgesics is expected to see a lower retail value growth rate in 2020. The COVID-19 pandemic is set to create a spike in demand for analgesics in this year, with higher sales related to ...

Used for pain relief in case of headaches, sore throat and fever, systemic analgesics are also often used as first response medication in case of flu, cough and cold in Pakistan. A fear of disease and a greater emphasis on health and hygiene will ...

Analgesics is expected to see the highest current value growth across all consumer health products in 2020. In particular, acetaminophen is expected to perform strongly. This is because reports worldwide in the first half of the year claimed that ...

When lockdown restrictions began to take effect in March, sales of analgesics received a welcome boost. Latvian consumers feared running out of products considered essential or that might help mitigate symptoms of COVID-19, stockpiling analgesics in ...

In 2020, fears of becoming infected and/or spreading the COVID-19 virus has convinced some Kenyans to avoid going out to health facilities and, in turn, they are increasingly turning to over the counter (OTC) analgesics, easily bought in pharmacies ...

As a result of the rumours about the negative impact of ibuprofen on consumers with COVID-19, sales of ibuprofen will see a significant drop in 2020. This comes on top of a slow year for ibuprofen sales in 2019, when DIGEMID warned against the use ...

Analgesics continues to show value growth in 2020, mainly driven by the increasing willingness of Tunisian consumers to self-medicate. This trend for self-medication is due to poor service from the medical system in the country, with hospitals ...

The outbreak of COVID-19 is expected to intensify the growth of acetaminophen, in 2020 as paracetamol is believed to be effective against some of the symptoms of COVID-19. This accounts for the dramatic increase in the current value growth rate of ...

Analgesics will see decent growth in 2020, benefitting from consumers fearing COVID-19 who stockpiled such products at the start of the outbreak. It will also benefit, as it has over the review period, from rising incomes and growing consumer ...

Analgesics are expected to register double-digit value growth in 2020, though not as high as value growth over the review period. However, a lot of value growth over the review period has been driven by inflationary pressure and but several product ...

COVID-19’s impact on sales of analgesics was mostly felt during the first six to eight weeks following the initial lockdown measures that were announced and implemented by local health authorities on 18 March. Overall security perception, including ...

Analgesics will be largely unaffected by the outbreak of COVID-19 overall. Although current value growth rates are anticipated to drop slightly, this will likely have little to do with the pandemic and more so following similar patterns seen over the...

The outbreak of COVID-19 encouraged consumers to purchase analgesics in Q1 and Q2 of 2020, through fear of catching the virus, with many consumers concerned that the pandemic would cause supply issues. This is set to result in positive value growth ...